1. INNOVATION PROJECTSSKOLKOVO FOUNDATIONBIOMEDICAL TECHNOLOGIES CLUSTER

2. 3ABOUT THE FOUNDATIONMissionGoalsEcosystemBenefits and opportunities for participantsStatistics and factsSkolkovo industrial partners: first success storiesBIOMEDICAL TECHNOLOGIES CLUSTERAbout the ClusterInnovation PrioritiesAchievementsPROJECTS OF PARTICIPATING COMPANIESCLUSTER CONTACTSPROJECTS OF PARTICIPATING COMPANIESIN ALPHABETICAL ORDER56778101112141415169094CONTENTS 3. 4 4. 5ABOUT THEFOUNDATIONMissionGoalsEcosystemBenefits and opportunities for participantsStatistics and factsSkolkovo industrial partners: first success stories67781011 5. 6Energy EfficiencyInformation TechnologiesBiomedical TechnologiesSpace Technology and TelecommunicationsNuclear&RadiationTechnologiesThe mission of the Skolkovo Innovation Center and the Skolkovo Foundation that established it, is to create an ecosystem in Russia conducive to the development of innovations to support cutting edge research and development and then to commercialize the results of such R&D in five priority fields of technological progress.The Skolkovo Foundation aims to ensure that the Innovation Center can provide facilities for the full cycle of the innovation process including education, R&D, experimental research and design, and commercialization of the results.The Skolkovo Foundation is creating a model for the development of an innovation-based economy for all of Russia. The Innovation Center serves as proving grounds to test the mechanisms for promoting the practical application of cutting edge ideas proposed by Russian academic and applied research institutions.SKOLKOVO IS A KEY ELEMENT IN THE SYSTEM OF RUSSIAN DEVELOPMENT INSTITUTESthat seeks to support innovation projects at every stage of development, from when its just an idea all the way through sales and marketing, creating a system of continuous support that startups can draw upon as they work on their projects. The Skolkovo Foundation focuses on the pre-seed and seed stages of business development and some of the aspects of the launch stage. Subsequent stages such as business growth and development, IPO and financing are supported by RV, RUSNANO and VEB, respectively.THE SKOLKOVO INNOVATION CENTER WAS ESTABLISHED BY FEDERAL LAW NO. 244 DATED SEPTEMBER 28, 2010 ON THE SKOLKOVO INNOVATION CENTER AS THE COUNTRYS RESPONSE TO THE NEW CHALLENGES OF THE GLOBAL ECONOMY: ACCELERATING TECHNOLOGICAL PROGRESS AND RISING COMPETITION FOR KNOWLEDGE AND COMPETENCIES BETWEEN LEADING NATIONS.education and R&Dexperimental design and researchcommercializationof the resultsMISSION OF THESKOLKOVO FOUNDATION 6. 7PARTNERSIndustrial partners (majorinternational and Russiancompanies), accredited VCinvestors.PARTICIPANTSThe kernel of the ecosystem, early-stagehigh tech startup companiesthat have been given the status ofSkolkovo project participants.EDUCATIONALENVIRONMENTSkoltech, OpUS,international and Russianpartner universities.TECHNOPARKLaboratory and researchinfrastructure.Infrastructure of SkolkovoInnovation Center.The ecosystem consists of the following key elements: startups, R&D centers of the industrial partners,venture capital investors, the Technopark, the Skolkovo Institute of Science and Technology (Skoltech)and the infrastructure, i.e. the town of Skolkovo.ESTABLISHING AN INNOVATION ECOSYSTEM INCLUDES CREATING AND DEVELOPINGEDUCATIONAL, RESEARCH AND ENTREPRENEURIAL ENVIRONMENTS, AS WELL AS THEPHYSICAL INFRASTRUCTURE OF THE SKOLKOVO INNOVATION CENTER.SKOLKOVO ECOSYSTEMSKOLKOVOS GOAL ISTO CREATE AN INNOVATION ECO-SYSTEMCONDUCIVETO RESEARCHAND ENTREPRENEURSHIPOpen University Skolkovo. 7. 8BENEFITS ANDOPPORTUNITIESFOR PARTICIPANTSTAX AND CUSTOMS BENEFITS: Social tax* - 14% Income tax - 0% VAT - 0% Property tax - 0% Customs tariffs on imported research equipment - 0 %* Insurance premiums paid by the employerHOW TO BECOME A PARTICIPANT:GRANT SUPPORTACCESS TO INFRASTRUCTURE AND CONSULTING: R&D infrastructure and common use centers, consultations forapplicants for Skolkovo participant status, office leases International and national events Education and mentoring (OpUS, Skoltech)HELP WITH RAISING FINANCE AND ACCELERATION: VC and angel investors Infrastructure and technologies offered by industrialpartnersCANDIDATESAPPLICANT01fills out the online form at www.sk.ruSKOLKOVO FOUNDATION02assesses the application based on formal criteria:) Have all the necessary information and documents been provided?b) Is the applicant a Russian legal entity?) Does the applicant meet the technology criteria of the Skolkovo Foundation?EXPERT PANELS03assess the project in detaila) Is it feasible in principle?b) What significant advantages does it offer over foreign competitors?c) What is its commercialization potential?d) Does the project team have the requisite experience to successfully implement the project on the international level?10 randomly selected experts from a large pool of expertsPARTICIPANT STATUS IS GRANTED TO THE APPLICANT~ one month 8. 9A business plan andan R&D program aredeveloped, the market isresearched and a searchfor investors is initiatedA working prototype ismanufactured, a tech-nicaldesign is developedand the concept istestedR&D is completed, anindustrial prototype isdeveloped and pre-clinicaltrials and phase I clinicaltrials are conductedR&D and clinical trials arecompleted, pilot batchesare manufactured andtrialedHOW FINANCING IS ALLOCATEDKEY PRINCIPLES FOR GRANT FINANCINGBY THE SKOLKOVO FOUNDATIONIdeaSeedEarlystageAdvancedstage15085049up toup toup toup toUp to100%SkolkovoGrant AmountPROJECT NEEDS MOREWORK (A MINI-GRANT MAYBE GIVEN )REFUSAL WITH EX-ORPLANATIONCo-Financing TermsMore than 75%Co-investorUp to 25%SkolkovoGRANTMEMORANDUMREVIEW BY THEFOUNDATIONGRANTCOMMITTEEAPPLICATIONThe participant prepares apresentation in accordancewith the recommendedformat and submits it viask.ruThe participant submitsthe grant memorandumwith appendixesThe Foundations ser-vicescheck the applica-tionand have it reviewedby external expertsPreparation for ameeting of the GrantCommittee10 days no more than 90 (+10) days ~ 1,5 months ~ 2 weeksThe Foundation decideswhether the presentationwill be reviewedThe Foundation checkswhether all the neces-saryinformation anddocuments have beensubmittedThe participant is noti-fiedof the results of thereviewThe Grant Committeedecides whether toaward a grantMore than50%Co-investorUp to50%SkolkovoUp to75%SkolkovoMore than25%Co-investor$ K$ K$ M$ M 9. 10STATISTICS AND FACTS5540applications from2010 through 2013484applicationsto registerintellectual propertyin 2013226approved grantsin 2010-2013$ 417 Mrevenue earned byparticipantsin 2012-2013$ 257 Min approvedgrantsin 2010-2013$ 91 Min financing fromexternal investorsin 201310000+jobsas of January 1, 2014 10. 11SKOLKOVO INDUSTRIALPARTNERS:FIRST SUCCESS STORIESIndustrial partners site their R&D centers in Skolkovo and act as startups customers, therebyintegrating the R&D and business environment in the Skolkovo ecosystem.industrial partnersestimated number of people to be employed by theR&D centers by 2015estimated total r&d budget through the end of 2015> 40> 3 500people> $ 943 MSKOLKOVO INDUSTRIAL PARTNERS TODAYKey Benefits of Skolkovo for Industrial Partners Access to the best human resources and cutting edge Russian science: Skolkovo is a good placeto work and thus is a magnet for the best specialists from all over Russia and Moscow. It is easy to carry out research and experiments thanks to the concentration of technology andhuman resources and cooperation with Skoltech, Russian research institutes, Skolkovo partners. Access to cutting edge technologies developed by Skolkovo resident startups, some of whichare being developed with state support. Simplified administrative procedures, no bureaucracy or red tape. The same tax and customs benefits as those enjoyed by Skolkovo participants. 11. 12 12. 13ABOUT THE CLUSTERAbout the clusterInnovation prioritiesAchievements141415 13. 14Cell or organ image analysis algorithmsComputational systems biology models and methodsCardio-vascular drugs & diagnosticsTools for large scale DNA or protein sequence analysisCell technologies for development of pluripotent or differentiated cells or tissuesMaterials & devices modifying structure, physiology, or development of tissues(clinical bioengineering)Anti-viral drugs, vaccines and diagnosticsMolecular modeling tools, molecular interaction models and toolsNeurological drugs & diagnosticsTranslational (personalised) medicine, biomarkersCancer drugs & diagnosticsImmuno-therapeutics, therapeutics for inflammationE-health, clinical informatics, and devices for patient monitoring, diagnostics,and therapeutic indicationsEndocrine drugs & diagnosticsABOUT THE CLUSTERINNOVATIVE PRIORITIESThe Clusters goal is to create a competitive biomedical technologies industry while bearing in mind that, in addition to trying to maximize revenue, were making a decisive contribution to improving the nations health.Our efforts have led to a significant increase in the number of companies seeking to commercialize science and biomedical technologies. As we try to promote this growth, we are seeing that the goal of the companies in our sector is improving healthcare. A healthy nation is a productive nation. Our mission is to support the development of biomedical technologies for a healthy and wealthy Russia.Kirill KaemVice President,Executive Director of the BioMedicalTechnologies Clusterof the Skolkovo Foundation 14. 15ACHIEVEMENTSThe Cluster brings together 238 innovative companies specializing in the development of innovative medicines, medical diagnostic and treatment products, new bio-compatible materials and cellular technology products.The companies have already created over 400 jobs. The Clusters startups generated total revenue of $ 51 K in 2013.The Cluster has given out 24 grants and 20 mini-grants (5 million rubles or less) for R&D.Clusters residents have been highly successful in their research and development efforts. Patent No. 2435783 Chimera Peptide and Pharmaceutical Composition for the Treatment of CancerousConditions issued to Skolkovo resident MetaMax was included in the top 100 Russian inventions of 2011, withthe list published by the Federal Service for Intellectual Property (Russian Patent Service). The findings of research carried out by OncoMax were presented at the Best Oral Presentations session ofthe 5th European Multidisciplinary symposium for urological cancers (EMUC) that was held in Marseilles onNovember 15-17, 2013. In 2011, Russias first ever Prix Galien Award in the Best Research nomination was given to AlexanderSobolev and Andrey Rosenkrantz from the Institute of Gene Biology of the Russian Academy of Sciences andVladimir Lunin (Gamaleya Epidemiology and Microbiology Research Institute) for the Modular Nano-transporterTechnology (MNT) they are working on. MNT can repeatedly increase the efficacy of drugs. Skolkovo-basedcompany Translek founded in 2011 is working on the commercialization of this technology. Hemacore Labs has developed a laboratory prototype of a device and technology for Thrombodynamics-4Danalysis (a new integrated, high-sensitivity hemostasis test that can easily detect disorders of both plasma-and platelet-mediated stages of blood clotting); a series of experiments were successfully carried out and theresults were presented in an oral presentation at the ISTH-2011 congress (Dashkevich et al, 2011); an articlewas published (Dashkevich et al, 2012) and was praised by the editorial staff of Stern magazine (2012). Eidos-Medicine has developed a series of robotic surgery simulators and successfully sold its first SurgerySimulator to the US-based corporation Covidien, one of the largest global manufacturers of medical equipment,in 2014. In March 2014, Fusion Pharma formed the first advisory board in Germany to address the clinical developmentof a new candidate drug for the treatment of drug resistant forms of chronic myelogenous leukemia, while at the2nd congress of Russian hematologists held in Moscow in April 2014 the company presented its findings to theinternational scientific community. The congress participants were extremely happy to hear that a breakthroughdrug could be just around the corner. Doctors are in urgent need of a new highly effective and safe drug for thetreatment of this condition. Another Cluster resident Incuron, LLC got an FDA approval in 2013 for the clinical trials of the new cancer drugCBL0137. The company successfully completed phase 1a trials in one year and is now enrolling patients forPhase 1b trials in the USA. Skolkovo resident 3D Bioprinting Solutions opened a laboratory in Moscow that is implementing an innovativeproject to develop 3D organ bio-printing. The company was founded by the Independent Laboratory Invitro. NovaMedica Innotech, LLC announced the creation of the research center in the Skolkovo Technopark tocontribute to the transfer of pharmaceutical products and technologies to Russia as well as to its in-houseresearch and development. In February 2014, Bind (RUS) opened a new R&D center in Moscow. The companys laboratories are going todevelop targeted drugs that utilize nano-particles for the treatment of cancers and other conditions. At the worlds largest fundamental cancer research congress organized by the American Association of CancerResearch held in San Diego on April 5-9, 2014, Russian Pharmaceutical Technologies presented the first resultsof pre-clinical trials of the new cancer drug RPT835. There was a keen interest at the congress in the newRPT835 inhibitor. 15. 16 16. 17PROJECTSOF PARTICIPATINGCOMPANIES BROKEN DOWN BY INNOVATION PRIORITIES 17. 18 18. 19CELL OR ORGAN IMAGE ANALYSIS ALGORITHMSTHE TECHNOLOGY OF 3D ORGANSBIOPRINTING FROM PATIENTSAUTOLOGOUS STEM CELLSCOMPETITIVE ADVANTAGES /- On-chip reconstruction of a functional nephron from human kidney cells with the basic kidney functions.- The nephron will be a prototype of an elementary structure for subsequent 3D-bioprinting of a kidney;- Considerable improvement of the potential nephrotoxicity assessment of new drugs thanks to a new technology, nephron-on-chip.INNOVATIONS MAIN POINT /Two kidney functions will be reconstructed in the nephron-on-chip: filtration and reabsorption.Existing or developed study models in 2D-cell models and in animals are insufficiently relevant and suffer a high degree of inaccuracy. Approx. 7% of new medicinal formulas worldwide do not reach the clinical trials stage due to nephrotoxicity discovered during the pre-clinical trials. 93% of the remaining formulas in phase I clinical trials have complications in 30-50% of patients in the form of acute renal failure because of nephrotoxicity.RESULTS ACHIEVED /- The initial stage of development.- A research laboratory has been built and equipped.- An international team of researchers has been formed. The project combines an intellectual potential and a unique experience of leading experts in the regenerative medicine.MARKET POTENTIAL/7% of new medicinal formulas worldwide do not reach the clinical trials stage due to nephrotoxicity discovered during the pre-clinical trials. 93% of molecules in phase I clinical trials have complications in 30-50% of patients in the form of acute renal failure.THE TEAM /ALEXANDER OSTROVSKYPhD (medicine), CEO of the biotechnological research laboratory 3D Bioprinting Solutions; Chairman of the Board of Directors, INVITRO.VLADIMIR MIRONOVScientific supervisor of the biotechnological research laboratory 3D Bioprinting Solutions, PhD(medicine).SERGEY NOVOSELOVHead of the researchlaboratory 3D Bioprinting Solutions, Doctor of Biological Sciences.CONTACTS /MoscowAlexanderOstrovsky+7 (499) 769-50-18 info@bioprinting.ru smirnova@bioprinting.ru Kashirskoyeshosse, 68,korp. 2, Moscow, Russiawww.bioprinting.ru3D BIOPRINTING SOLUTIONS 19. 20TECHNOLOGY OF EXTREMITY PROSTHESIS MANAGING WITH THE AIDOF BRAIN-COMPUTER INTERFACECOMPETITIVE ADVANTAGES /A technology for comfortable noninvasive control by the manipulator (including prosthesis) is under development.MAIN POINTS OF INNOVATION /Neural controller will allow to detect volitional impulse to different movements in the patterns of the human brain biological currents and transform them into commands for prosthesis electromechanical actuators. A person will be able to move prosthesis / manipulator with mere intention to action.ACHIEVED RESULTS /2013-2014 - The development and improvement of neural controller prototype.2015-2016 Release of neural controller into the market.8 scientific articles in the international and Russian journals have been published.MARKET POTENTIAL /Precision of processing and detection of brain signals is up to 95% versus 80 - 85% for the most advanced international interfaces.THE TEAM /ALEXANDER KAPLAN,Doctor of Biological Sciences, Prof.The project involves an experienced team in the area of neurophysiology, with many years experience in successful research in the field of human neurophysiology at major Russian and foreign specialized centers (Japan, Germany, South Korea).INNOVATECHCONTACTS /MoscowAlexander Kaplan+7 (495) 939-13-73akaplan@mail.ruwww.brain.bio.msu.ruCOMPUTATIONAL SYSTEMS BIOLOGY MODELS ANDMETHODS 20. 21INFORMATION PLATFORM FOR BIOMEDICAL DATA ANALYSIS AND DEVELOPMENTOF INNOVATIVE DRUG PRODUCTSCOMPETITIVE ADVANTAGES /The high modularity of the platform will allow to create a large number of programs covering all areas of bioinformatics and systems biology, necessary to create innovative medication.MAIN POINTS OF INNOVATION /Conveyor system from the genome to the drug for conducting researchin the area of biomedical data analysis and drug discovery with the use of software modules for BioUML platform and experimental validation of the computer forecast.ACHIEVED RESULTS /First commercial version of the platform successfully commercialized under the name geneXplain platform has been launched. A prototype of BioStore trading platform has been developed and launched intooperation. 85 research papers have been published in the Russian and international journals.MARKET POTENTIAL /The global bioinformatics market will reach $ 8.3 billion in 2014, while the bioinformatics platform market willbe the largest and will be estimatedat $ 3.9 billion.THE TEAM /ALEXANDER KEL,PhD (Biology), CEO.FEDOR KOLPAKOV,PhD (Biology), Executive Director.VLADIMIR POROYKOV,Doctor of Biological Sciences, Prof., ResearchDirector.EDGAR VINGENDER,Prof., Director of Bioinformatics Department,University Medical Center Gttingen.ALEXANDER TROPSHA,Prof. and Deputy Dean for Academic Affairs inEshelman School of Pharmacy, UNC-Chapel Hill, NC, USA.BIOSOFT.RUCONTACTS /NovosibirskAlexander Kelalexander.kel@biosoft.rufedor@biosoft.ruwww.biosoft.ruCOMPUTATIONAL SYSTEMS BIOLOGY MODELS ANDMETHODS 21. 22 22. 23COMPETITIVE ADVANTAGES /The most promising and easy-to-use class of anticoagulants. Exceeds all known analogs for human blood plasma activity. Modifications show world-leading values for the most important blood clotting parameters (DD217).MAIN POINTS OF INNOVATION /Modeling based on a protein chain structure accounting for physical and chemical properties of the molecule and selection of molecule class accounting for patent non-infringement. Close monitoring of experimental work via computer modeling with instantaneous feedback.ACHIEVED RESULTS /DD217 has been studied for acute toxicity, mutagenicity, and subchronic toxicity. A dosage form is indevelopment, stability studies are underway, and a pilot synthesis method is being developed.MARKET POTENTIAL /The substance classes have been patented. Development in Russia: has a potential under the Pharma 2020 Strategy. The Russian market of anticoagulants (ATX B01 group) in 2010 was estimated at 6.57 billion rubles (Remedium).THE TEAM /DMITRY TOVBIN,PhD in Physics and Mathematics, CEO;NIKOLAI TARASOV,PhD inPhysics and Mathematics, Chief Science Officer;DMITRY MALAKHOV,PhD in Chemistry, Chief Chemist;ARSENY AYBUSHEV,PhD inPhysics and Mathematics, Programmer/Developer;VLADIMIR GORSHKOV,PhD in Chemistry, Chemist;DMITRY SYCHEV,Doctor of Medicine, Project Development Consultant.ORIGINAL NEXT-GENERATION ORALANTICOAGULANT, DIRECTFACTOR XA INHIBITORPHARMADIALL LLCCONTACTS /MoscowDmitry Tovbin+7 (903) 761 27 17dtovbin@didiall.comul. Kakhovka, 10, korp. 3CARDIO-VASCULAR DRUGS & DIAGNOSTICS 23. 24TECHNOLOGY FOR TREATING ATHEROSCLEROSIS OF HUMAN BLOOD VESSELS USING CHEMICALLY MODIFIED NANOPARTICLESCOMPETITIVE ADVANTAGES /Chemically modified carbon-containing nanoparticles can be used as coatings for vascular stents, and as the main substrate in columns for extracorporeal blood purification. The solution has lower price and higher efficacy.MAIN POINTS OF INNOVATION /Creation of hybrid organic modified nanomaterials with prescribed surface properties. The technology can hybridize under the mildest conditions possible with high efficacy using a simple hardware design.ACHIEVED RESULTS /A technology has been developed to synthesize the necessary nanomaterial (carbon-containing nanoparticles with dimensions up to 10 nm); proof of concept has been demonstrated for chemical modification of carbon-containing nanoparticles with lipophilic properties.MARKET POTENTIAL /There are no biologically active modified nanoparticles with the given affinity to plaque components currently on the market. Nanoparticles can be used in the production of next-generation coronary and vascular stents.THE TEAM /SHAMIL AKHMEDOV,Project Director;Scientific Consultants:VIKTOR FILIMONOV;SERGEY AFANASYEV;PAVEL POSTNIKOV;YANA ANFINOGENOVA;ANDREY GALANOV.CONTACTS /TomskShamil Akhmedovashd@mail.ruRussia, Tomsk Oblast,Tomsk,ul. Ivana Chernykh,5260NANOKOR LLCCARDIO-VASCULAR DRUGS & DIAGNOSTICShealty arteryblood flownarrowed arterywith atherosclerosisatheroscleroticplaque 24. 25HARDWARE AND SOFTWAREFOR ATHEROSCLEROSISAND CARDIOVASCULARDISEASEPREDICTIVE GENE TESTINGCOMPETITIVE ADVANTAGES /The new product has no direct analogues. The number of potential users of this service in Russia in 2012 is roughly 35 million people.MAIN POINTS OF INNOVATION /The institute is developing a method and predictive gene testingfor atherosclerosis based on analyzing mutations in the mitochondrial genome. Implementing this method results in early diagnostic of atherosclerosis.ACHIEVED RESULTS /Scientific research and basic clinical epidemiology studies have been completed, test prototypes ofdiagnostic kits to be used with hardware and software have been developed along with the hardware and software schematic diagram.MARKET POTENTIAL /The market for early atherosclerosis predictive gene testing is practically undeveloped, so the market share cannot be determined as of yet.THE TEAM /ALEXANDER OREKHOV,General Director;IGOR SOBENIN,Atherosclerosis Treatment Center DirectorALEXANDER FEOKTISTOV,Biochemical Research Group Lead;VARVARA OREKHOVA,Inpatient Clinic Department Manager;NIKITA NIKIFOROV,Cell Biology Department Manager.INSTITUTE FOR ATHEROSCLEROSIS RESEARCH LLCCONTACTS /MoscowAlexander Orekhov+7 (495) 415 95 94a.h.opexob@gmail.comBagrationovskyproezd, d. 3www.inat.ruCARDIO-VASCULAR DRUGS & DIAGNOSTICS 25. 26COMPETITIVE ADVANTAGES /EMC Corporation specialists are participating in the project. A license agreement with Life Technologies is in development to provide special conditions for developing clinical applications for semiconductor sequencing technology.MAIN POINTS OF INNOVATION /Integrated automation of the process from loading the sample in the sample prep station through sequencing, analysis, and data interpretation. The project is aimed to achieving the goals of personalized medicine and genomic diagnostics.ACHIEVED RESULTS /The Ion PGM semiconductor DNA sequencing system was successfully launched in 2012. Clinical tests have been performed. A software beta version has been developed in conjunction with Reksoft to analyze genomic data.MARKET POTENTIAL /The development project comprises a hardware and software complex that allows geneticists to analyze patients genomic data.THE TEAM /ALEXANDER PAVLOV,Project Director;ARSENY SMIRNOV,Medical GeneticsDirector;DMITRY POLYNTSEV,Financial Management;ANTON BRAGIN,IT Solutions, GeneticData Analysis Software.UNIQUE INTEGRATED SOLUTIONS FORMOLECULAR GENETICDIAGNOSTICS INTENDED TO IMPROVEPERSONALIZED MEDICINESEQUOIA GENETICS LLCCONTACTS /St. PetersburgAlexander Pavlov+7 (812) 677 65 35apavlov@alkorbio.ru192148, Russia, St. Petersburg,ZheleznodorozhnyProspekt, 40 Awww.sequoiag.ruTOOLS FOR LARGE SCALE DNA OR PROTEIN SEQUENCEANALYSIS 26. 27TOOLS FOR LARGE SCALE DNA OR PROTEIN SEQUENCEANALYSISKITS FOR MOLECULARDIAGNOSTICS IN ONCOLOGYCOMPETITIVE ADVANTAGES /The increased sensitivity of the test, the possibility to analyze mutations without biopsy (by blood testing). The possibility of lung cancer testing without bronchoscopy. he possibility of testing patients with unresectable tumors.MAIN POINTS OF INNOVATION /Highly-sensitive test of EGFR mutations in blood plasma DNA based on the new version of multiplex polymerase chain reaction (PCR) and allele-specific PCR in real time mode.ACHIEVED RESULTS /The project is searching for financing to carry out R&D.Development of the test technology on themodelsamples is ongoing. The project is searching for financing to complete R&D.MARKET POTENTIAL /The cost of one set production(running cost after R&D) is 10-15 USD in mass production. Selling price is USD 100-200 (Russia) and USD 500-1,500(Western Europe).Possible market share for the Russian manufacturer is 1-3%, i.e., approximately USD 80-200 million per year.THE TEAM /ALEXANDER KORNIENKO,CEO;SERGEY KOVALENKO,CSO;VLADIMIR SHAMANIN,Head of R&D;NATALIA MATSENKO,Research Assistant;LEV PETRENKO,Research Assistant.BIOLINK LLCCONTACTS /NovosibirskSergey Kovalenko+7 (383) 334 86 14 biolink@inbox.ruRussia, Novosibirsk Region, Novosibirsk,ul. Timakova, 2www.biolinklab.ru 27. 28COMPETITIVE ADVANTAGES /Lower costs with higher treatment efficiency compared to standard treatment. Absence of the negative systemic effects on the immune system compare to conventional immunosuppressive drugs , absenceof side effects.MAIN POINTS OF INNOVATION /We offer a new approach to the Multiple Sclerosis treatment - targeted cell therapy, based on adoptive transfer of deficient autologous T cells with immuno suppressive ability. Compensation of deficiency of the regulatory cells in patient. Patented way of autologous regulatory T-cell expansion providesa 1000-1500-fold increase in the number of cells within a short period of time(7 days). The vitality and full capacity of expanded cells is proved.ACHIEVED RESULTS / Technology developed and patented.Patent RU 2437933C1, US Patent 8,697,060 B2International Patent Application claiming priority to RU 2012127158; POC in human: Multiple Sclerosis -14 patients : safe, no side effects, prevent relapses; EDSS stabilized over two years;MARKET POTENTIAL /Disabling and fatal disease, patients aged 20-50 years. The Costs of treatment ~$25000 per year. More than 2.5 million people worldwide suffer from multiple sclerosis. Total number of patients with autoimmune diseases is more than40 million. This therapy also can be effective in the treatment of other autoimmune diseases: rheumatoid arthritis, SLE, diabetes type I, psoriasis, etc.THE TEAM /SVETLANA BYKOVSKAYA,MD, Prof., CEO, Project Research Manager;YEVGENY NASONOV,MD, PhD, scientific consultant;ANASTASIA LOCHONINA,the scientist.AUTOLOGOUS T-REGULATORY CELL VACC INE FOR AUTOIMMUNE DISEASES TREATMENT WITHOUT TOTAL IMMUNE SUPPRESSIONREGENEXCONTACTS /MoscowSvetlana Bykovskaya+7 (916) 436 22 91Sbykovskaia@gmail.comwww.roscardioinvest.ruCELL TECHNOLOGIES FOR DEVELOPMENT OF PLURIPOTENTOR DIFFERENTIATED CELLS OR TISSUES 28. 29COMPETITIVE ADVANTAGES /The optimal combination of physical chemistry, mechanics, technology, and biomedicine parameters of tissue bioconstructors will improve the efficacy of regenerative medicine, create a new class of implants, and expand the spectrum of medical services.MAIN POINTS OF INNOVATION /Improvement of medical implants. Biomedical parameters, biomechanical material properties, and processes at the artificial materialbiological tissue interface are important for successful grafting and functioning of implants.ACHIEVED RESULTS /Clinical trials of the product are underway. Test prototypes have been produced. The team is searching for co-investors and partners.MARKET POTENTIAL /The resulting implants have a wide range of applications in orthopedics, stomatology, surgery, etc.THE TEAM /IGOR KHLUSOV,CEO;YURI DEKHTYAR.PROJECT PARTNERS:Siberian State Medical University (Tomsk);Riga Technical University (Latvia);Institute of Strength Physics and Materials Science of the Siberian Branch of the Russian Academy of Sciences;Biology Department at Lomonosov Moscow State University.CONCEPT AND IMPLEMENTATION OF TISSUE BIOCONSTRUCTOR TECHNOLOGIESIN REGENERATIVE MEDICINEBIOKONSTRUKTOR-S LLCCONTACTS /TomskIgor Khlusov+ 7 (913) 823 39 62khlusov63@mail.ruRussia, Tomsk Oblast,Tomsk,ul. Sibirskaya, 31,apt. 319CELL TECHNOLOGIES FOR DEVELOPMENT OF PLURIPOTENTOR DIFFERENTIATED CELLS OR TISSUES 29. CELL TECHNOLOGIES FOR DEVELOPMENT OF PLURIPOTENTOR DIFFERENTIATED CELLS OR TISSUES30DENDRIVAX ANTICANCER VACCINE BASEDON DENDRITIC CELLS WITH A NEWGENERATION ADJUVANTCOMPETITIVE ADVANTAGES /The novelty of the approach is to activate dendritic cells (DCs) in situ and to use allogeneic cell adjuvant that stimulates a cytotoxic T-cell response, which reduces the costs and increases the effectiveness of the vaccine.MAIN POINTS OF INNOVATION /Development and introduction into clinical practice of DendriVax immunotherapeutic vaccine based on DCs with a new generation adjuvant for treatment of hormone-resistant prostate cancer and other solid tumors.ACHIEVED RESULTS /A pilot clinical trials have been conducted in Philippines and in the United States to prove basic technology. The concept of a new generation adjuvant was developed and patented. The plan of transfer and scaling of core technology in Russian Federation has been formulated.MARKET POTENTIAL /A real alternative to chemotherapy will appear in the market for treatment of stage III-IV prostate cancer, increasing life expectancy and improving patients quality of life.THE TEAM /OLEG EGOROV,CEO;VASILIY OSCHEPKOV,Medical Director;IRINA BALDUEVA,Head of the Production Laboratory, ChiefInvestigator;BENJAMIN TJOA,Production Expert;WILLIAM CAVANAGH,Clinical Trial Expert;MIKHAIL KISELEVSKIY,Dr. Bio. Sc., Prof., Scientific ConsultantCONTACTS /MoscowOleg Egorovvlad.v.egorov@gmail.com115419, Russia, Moscow,ul. Ordzhonikidze, 11,build. 2MEDVIO EURASIA LLC 30. 31COMPETITIVE ADVANTAGES /The proposed technology is highly competitive due to original patents for cell culture technique and test systems developing.MAIN POINTS OF INNOVATION /Creation of hereditary neurodegenerative diseases cell models and test systems (based on iPS cells) for normal specialized human cells drugs creening using the companys new technology.ACHIEVED RESULTS /The company studies genetic components of the pathologies of hereditary neurodegenerative diseases for which there are currently no effective treatments.MARKET POTENTIAL /Currently there are no development of original drugs in Russia, which is why the main target is the global pharmaceutical development market.THE TEAM /ROMAN DEEV,General Director;ILYA BOZO,Research Scientist.PROJECT PARTNERS:HSCI OJSC (Human Stem Cells Institute)TEST SYSTEMS FOR DISEASEPATHOGENESIS STUDYINGAND DRUG DEVELOPINGNEXTGEN LLCCONTACTS /MoscowRoman Deev+7 (965) 147 12 77bozo.ilya@gmail.comul. Gubkina, d. 3, korp. 1www.hsci.ru/o-kompanii/struktura-gruppy-iskchCELL TECHNOLOGIES FOR DEVELOPMENT OF PLURIPOTENTOR DIFFERENTIATED CELLS OR TISSUES 31. 32ZEDIGUS - TECHNOLOGY OF THEPRODUCTION OF TARGETED SMART DRUGS FOR THE TREATMENT OF PURULENTAND GUNSHOT WOUNDS AND DIABETIC FOOTCOMPETITIVE ADVANTAGES /Targeted delivery and retention of antibiotics in the focal point of wound infection. Overcoming of the development of multidrug-resistant pathogens, which cause the development of wound infection.MAIN POINTS OF INNOVATION /Application of integration of technologies (nano-, bio-, and engineering) to create innovative drug molecules -biointerface effect.ACHIEVED RESULTS /The first samples of the unique ointment were obtained that demonstrated the effectiveness in the treatment of severe and complicated injuries, including septic, gunshot, diabetic foot, venous ulcers and non-healing ulcers in cancers.MARKET POTENTIAL /The volume of sales of ointments in Russia was 9.1 bln rubles in whole sale prices in 2011. Sales volume reached 218.5 mln packages in physical term (+17.0% compared to 2010) (IMS Health).THE TEAM /MIKHAIL EPINETOV,Doctor of Medicine , Prof., CEO;VALERY MIKHAILOVICH DEMBITSKY,Doctor of Chemical Science, Prof., Pharmachemist-Technologist;NIKOLAI LVOVICH SHIMANOVSKY,Doctor of Medicine, Prof., Molecular Pharmacologist;VLADIMIR VITALIEVICH MELNIKOV,Doctor of Medicine, Prof., Surgeon- Researcher.CONTACTS /AstrakhanMikhail Epinetov+7 (8512) 34 23 21epinetov@mail.ruinfo@astlek.comRussia, Astrakhan Region,Astrakhan, ul. Tatishcheva,20, block. A, of. 415www.astlek.comSCIENTIFIC PRODUCTION MEDICAL AND PHARMACEUTICAL ESTABLISHMENT ASTLEK LLCMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 32. 33DEVELOPMENT OF A LASER SYSTEM FORMINIMALLY INVASIVE SURGERYCOMPETITIVE ADVANTAGES /Incision of biological tissues within the accuracy of 50 microns,Absence of bleeding,It does not cause thermal damage to the tissue cells;It possesses potent sterilizing effect;It reduces the time of operation,Scar tissue is not formed at the site of the incision.MAIN POINTS OF INNOVATION /An unique method was developed of minimally invasive surgeries by cold ablation of biological tissues with laser radiation energy to the desired depth controlled by a physician in the conditions of complete hemostasis, as well as a laser system for its implementation.ACHIEVED RESULTS /The prototypical 2940 nm laser has diode pumping and transmission of laser radiation through ZBLAN optical fiber to the operated tissue. Cold ablation of tissues without their thermal damage was carried out in vitro.MARKET POTENTIAL /During surgery, the effective incision or evaporation of abnormal tissue is provided without signs of heat damage with the simultaneous cessation of bleeding. These results were never achieved before.THE TEAM /NADEZHDA FASHUTDINOVA,Project Manager, Company Director;OLEG KUZMIN,Head of R&D;OLGA RISOVANNAYA,Medical Research Program Manager.8 engineers, 2 technicians with experience in the development of laser equipment for civilian and military applications are involved in the implementation of the project.CONTACTS /KrasnodarOleg Kuzmin+7 (988) 246 96 46kuzmin@photonics-biotech.com350063, Russia, Moscow, ul. Komsomolskaya, 13LASER BIOMED LLCMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 33. 34CONTACTS /St. PetersburgAlexander Malygin+7(812)328 42 51 malygin.av@gmail.com 191186, Russia, St. Petersburg,NevskyProspekt, 30COMPETITIVE ADVANTAGES /Improves the hearing in 89% of patients with sudden and acute hearing loss and 67% of patients with chronic hearing loss, regardless of cause. Tinnitus ceases or lessens in 91% of patients.MAIN POINTS OF INNOVATION /An unique patented technologyofaudioselectivetranscranial electric stimulation of protective (endorphin) mechanisms of the brain using pulse current in conjunction with acoustic impact on the acoustic organ with tonal signals at the hearing loss frequencies.ACHIEVED RESULTS /A line of devices has been produced based on the fundamental technology for treating disorders of various etiologies. Development of a method of treating sensorineural hearing loss has begun based on TES therapy in conjunction with acoustic impact.MARKET POTENTIAL /The audiology equipment market will reach 26.2 billion dollars by 2017 (Audiological Devices -Global Strategic Business Report). The US market of mobile medical devices is 15 million devices (HIMSS Analytics).THE TEAM /ALEXANDER MALYGIN,PhD in Engineering, CEO;VALERY LEBEDEV,Doctor of Medicine, Professor, RANS Academician,Science Division Director;DMITRY TSEITLIN,PhD inMedicine, Clinical Trials and Commercialization Director;ANNA BELIMOVA,PhD inMedicine, Audiologist.PROJECT PARTNERS: TES Center LLCMOBILE TECHNOLOGY FORTREATING SENSORINEURALHEARING LOSS AND TINNITUSTES MOBILE LLCMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 34. 35COMPETITIVE ADVANTAGES /The valve has three cusps, which will ensure the axial blood current, thus creating conditions close to the physiological ones. Improves patients quality of life, reduces anticoagulant consumption, noise level, blood hemolysis and the likelihood of repeated implantation.MAIN POINTS OF INNOVATION /A novel tricuspid cardiac valve combines the advantages of mechanical and biological valves. The major advantage of the tricuspid cardiac valves is the availability of the axial blood current, which reduces the thrombus formation rate.ACHIEVED RESULTS /The functional and robustness parameters undergo preliminary testing.Clinical trials of the product are planned, coupled with physical and chemical studies of materials and with the refinement of engineering processes.MARKET POTENTIAL /A marketing authorization from the Federal Service for Supervision of Healthcare and Social Development has been obtained, permitting manufacture, sales and application of the new tricuspid cardiac valve Tricardis.THE TEAM /ALEXANDER SAMKOV,PhD in Engineering, CEO;REGINA KEVORKOVA,mechanical engineer, deputy CEO for science;ANTONINA MAKEEVA,electronics engineer, commercial manager.DEVELOPMENT OF SKL - AN INNOVATIVE TRICUSPID BIOMECHANICALARTIFICIAL CARDIAC VALVE USINGPOLYMERIC COMPOSITE MATERIALEMITRON LLCCONTACTS /MoscowAlexander Samkov+7 (499) 127 46 06 roscardioinvest@ yandex.ru Bldg. 1, 20 Nagornayaul., 117186 Moscow, Russia www. roscardioinvest.ruMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 35. 36CONTACTS /MoscowPavel Zaburski+7 (916) 706 77 12zaburski@inbox.ruBldg. 2, 4 Verbnayaul.,107143 Moscow, Russiawww.abiotex.ruDEVELOPMENT OF DENTAL IMPLANTCOATING THAT WILL STIMULATEOSTEOGENY AND PROVIDETARGETED IMPACT ON REGENERATIONPROCESSES IN PERIIMPLANT TISSUESCOMPETITIVE ADVANTAGES /The haemostatic activity may partially or fully lift restrictions on traditionally absolute counterindications to implants of patients with idiopathic or symptomatic violations of the blood coagulability function.MAIN POINTS OF INNOVATION /The coating being developed is a combination of biologically active ingredients. The substances that are components of the coating exert direct influence in the precursor cells, thereby inducing osteogeny in the implantation area.ACHIEVED RESULTS /A material of titanium-made surface coating has been obtained that contributes to osteointegration and displays bactericidal properties. The technology of applying an organic coating onto titan is being refined.MARKET POTENTIAL /To date, the Russian implantology market is evaluated at 500,000 implants per year. The Russian market shows a tremendous demand for high-quality implant services.THE TEAM /PAVEL ZABURSKI,CEO;ILYA FRIDMAN,co-founder of Alpha Biotech LLC;OFIR FROMOVICH,consultant for major development areas and evaluation of declared parameters;SERGEY KISELEV,head of technology and engineering solutions department;MIKHAIL YASINOV,research fellow.ALPHA BIOTECH LLCMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 36. 37COMPETITIVE ADVANTAGES /Jointech synovial shunt is a new method of treatment of knee joint effusion. It is implanted in a minimally invasive way with by means of specially developed minimally invasive delivery system.MAIN POINTS OF INNOVATION /A synovial shunt is an implant made of nitinol alloy with self-retaining mounts on two opposite sides of the implant. This allows the implant to remain in a fixed position within the joint after implantation.ACHIEVED RESULTS /Clinical trials were carried out by European standards. Technical and regulatory documents are prepared. The possibility of using of Jointech synovial shunt in patients is being assessed.MARKET POTENTIAL /Only in 2010 over 4,000,000 arthroscopies were performed in the USA, with the prevailing share of arthroscopy of knee and shoulder. The market of arthroscopy of knee joints in the USA is estimated by the company to be more than USD 1 billion.THE TEAM /SVETLANA ZENKOVA,CEO;DMITRY KOTEGOV,Vice President of Business Development;ALEXANDER OZEKH,Manager of the Medical Department;ROY SHAFRIR,Coordinator of Research and Development;LEONID WAXMAN,Medical Business Development Consultant.JOINTECH SYNOVIAL SHUNTIS A MINIMALLY INVASIVE THERAPYFOR KNEE JOINTSJOINTECH RUS LLCCONTACTS /YekaterinburgDmitry Kotegov+7 (963) 275 22 20Kotegovd@yandex.ruRussia, Sverdlovsk Region, Yekaterinburg,ul. Lunacharskogo 31, of. 317MATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 37. 38DEVELOPMENT AND RUSSIAN MARKETRELEASE OF NEW MEDICAL LASERSYSTEMS FOR SOFT AND HARDTISSUE SURGERYCOMPETITIVE ADVANTAGES /This modular laser system has several advantages in use:- universal application and possible upgrades;- compactness and portability;- large, easy-to-use touchscreen;- intuitive navigation and easy-to-use menu.MAIN POINTS OF INNOVATION /stLase surgical laser system with microprocessor control, touchscreen, and graphic operator interface, with power transmitted through fiber optic cable, contact, or contact-free methods.ACHIEVED RESULTS /The first lot (5 devices) of universal consoles withstLase modules have been producedfor trainingdoctors, demonstrations, and initial sales.The stLase PE module is in development.MARKET POTENTIAL /The company works in close partnership with the international companies Dental Photonics and Laser Abrasive Technologies, as well as leading Russian institutes and organizations.THE TEAM /VYACHESLAV SELIVANOV,CEO;GRIGORY ALTSHULER,Doctor of Engineering, Chief Scientific Advisor;IGOR SHUGAYLOV,Doctor of Medicine, Professor, Chief Medical Advisor.PHOTONICS LLCCONTACTS /MoscowVyacheslavSelivanov+ 7 (495) 411 69 92info@laserphotonics.ruul. Yakimanka B., 1www.laserphotonics.ruMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 38. 39DEVELOPMENT ANDMANUFACTURING OF HI-TECHSURGICAL TOOLS FOR BALLOON KYTHOPLASTYCOMPETITIVE ADVANTAGES /The innovative medical product for balloon kythoplasty excels its analogues and has the market price 23 times lower than the competitors offer.MAIN POINTS OF INNOVATION /The balloon kythoplasty method served as a basis for the development of unique hi- tech medical tool used in the treatment of patients with spinal fractures.ACHIEVED RESULTS /A unique hi-tech medical tool that complies with the gold standards for a treatment of spinal compression fractures has been developed.MARKET POTENTIAL /A forecast of the global market of surgical tools for balloon kythoplasty is more than $ 950 mln in 2014. The potential customer base for a treatment is about 2 bln rubles.THE TEAM /ALEXANDER TOMA,PhD in Medicine, neurosurgeon, CEO;MEDIATOMA LLCCONTACTS /SaratovAlexanderTomaal_toma@mail.ru8 S.M. Kirovaprospekt, 410600 Saratov,Saratov region, Russiawww.mediatoma.ruMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 39. MATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING40COMPETITIVE ADVANTAGES /Multifunctionality is several tools built in one arm. Many degrees of freedom of movement. The relative cheapness of the robot without loss of functionality, while maintaining the advantages of robotic surgery.MAIN POINTS OF INNOVATION /MeMic system is a maneuverable medical robot with 18 degrees of freedom (DOF), integrated set of tools and is 12 times smaller than the surgeons hands.ACHIEVED RESULTS /The manufactured plastic laboratory prototype is tested for gripping movements of the operators hand and for their conversion into movements of the manipulator. The experiments with holding the needle and making sutures using two manipulators are under way.MARKET POTENTIAL /By 2016, the market of micro-invasive surgery will reach USD 35.5 bln. The surgeon armamentarium represents the largest segment of the market. Potential revenues could reach USD 651 mln + USD 65 mln would proceed from maintenance.THE TEAM /SVETLANA ZENKOVA,CEO;Dr. NIER SCHWALB,Research, Scientific and Technical Consultant;Dr. YOAV MINTZ,Medical Director;XENIA CHAGAN,Business Consultant.MEMIC - A ROBOTIC MANIPULATORFOR LAPAROSCOPYMEMIK EVROPA LLCCONTACTS /YekaterinburgSvetlana Zenkovasvetik_z2001@mail.ruRussia, Sverdlovsk Region, Ekaterinburg, ul. Lunacharskogo, 31, of. 304 B 40. 41UNIVERSAL BIODEGRADABLEINTRAVASCULAR IMPLANTS (STENTS)THAT RESTORE BLOOD CIRCULAT ION.AN ALTERNAT IVE TO METAL ANALOGUESCOMPETITIVE ADVANTAGES /Restore a blood circulation in vessels likemetallic stents, but in contrast to themthey dissolve completely after several months.The vessel restores its normal function,including motility. They prevent localinflammation at the place of positioning andrestenosis.MAIN POINTS OF INNOVATION /Use of innovative multi-component polymercompound as the material for stentsprovides the following advantages:- It simplifies the design of stents;- It improves the mechanical properties asCompared with existing stents.ACHIEVED RESULTS /A thermoplastic polymer compound hasBeen developed.Prototypes of biodegradable stents withSpecified mechanical parameters have been obtained.A primary test for histocompatibility andBiological safety has been performed.Patent protection of the technology hasBeen implemented.MARKET POTENTIAL /The global market of coronary stents in2016 will reach $ 10.6 billion*.Expected market annual growth rate - 8.3%(BCC Research estimate).THE TEAM /MIKHAIL POPOV,CEO.OKSANA MANZENYUK,PhD in Medical Sciences, Deputy CEO,Project Manager.NIKOLAI SOLOVYOV,Doctor of Physical and MathematicalSciences,Chief of Laboratory of Laser Discharges,Instituteof Mechanics of the RussianAcademy of Sciences(IPMechRAS).DMITRY KAPUSTIN,PhD in Chemical Sciences, PolymersforBiology laboratory, M.M. Shemyakinand Yu.A. Ovchinnikov. Institute ofbioorganic chemistry of the RussianAcademy of Sciences (IBChRAS).BIOSTENCONTACTS /MoscowOksana Manzenyuk+7 (495) 787 37 34o.manzenyuk@stentex.ru m.popov@stentex.ruMATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING 41. 42COMPETITIVE ADVANTAGES /The use of hLf APO with interferons and ribavirin reduces treatment duration on average from one year to 21 days and increases efficacy from 41% (Pegasys) to 80%.MAIN POINTS OF INNOVATION /Human lactoferrinapo (hLf APO) is lactoferrin with low iron saturation that interacts with hepatitis C virus; when the virus is titered in the blood, its amount decreases and the virus completely disappears (21 days).ACHIEVED RESULTS /The project is in the seed stage. The drug has been in research since 2000 and shows stable, positive results, which indicates that further studies are needed during drug approval.MARKET POTENTIAL /The hepatitis C treatment project is ambitious and revolutionary and has high potential for commercialization. The projects research risks are low, as twelve years of studies show stable, positive results for treating hepatitis C.THE TEAM /SERGEY LESHKOV,CEO;NIKOLAI SHATUNOVSKIY,Project Science Director;EVGENY EFREMOV,Project Scientific Consultant.NEW DRUGS AND MEDICAL DEVICESFOR TREATING PATIENTS WITHVIRAL HEPATITIS CINNOVATIVE MEDICINE LABORATORY CJSCCONTACTS /MoscowSergey Leshkovsleshkov@list.ruul. Berzarina, 16ANTI-VIRALDRUGS, VACCINESANDDIAGNOSTICS 42. ANTI-VIRAL DRUGS, VACCINESANDDIAGNOSTICS43DEVELOPMENT OF ORIGINAL DRUGSFOR TREATING VIRAL INFECTIONSAND METHODS FOR DIAGNOSINGVIRAL DISEASESCOMPETITIVE ADVANTAGES /Triazavirin has the complex advantages:- lack of side effects and activity against resistant forms of viruses;- several dosage forms (including those under development);- price.MAIN POINTS OF INNOVATION /An unique lab complex is being created for discovery research. Pilot projects are being organized to develop and scale up technologies for producing finished dosage forms of antiviral drugs.ACHIEVED RESULTS /The company has developed 15 original first-in-class active ingredients that are currently in virologic testing. Finished dosage forms have been developed for the first-in-class drug Triazavirin.MARKET POTENTIAL /By 2020, the company plans to hold up to 40% of the Russian antiviral drug market and enter the global market.THE TEAM /VALERY CHARUSHIN,RAS Academician;OLEG CHUPAKHIN,RAS Academician;VLADIMIR RUSINOV,RAS Corresponding Member.URAL CENTER FOR BIOPHARMACEUTICALTECHNOLOGIES LLCCONTACTS /Novouralskinfo@ucbt.uphc.ruRussia,Sverdlovsk Oblast,Novouralsk,ul. Podgornaya, 11 43. 44ANTI-VIRALDRUGS, VACCINES AND DIAGNOSTICSCOMPETITIVE ADVANTAGES /A new class of molecules with activity against HBV characterized as an inhibitor of virus particle penetration into the cell. The mechanism of action ensures long- term eradication of HBV and prevents viral hepatitis D.MAIN POINTS OF INNOVATION /Myrcludex B is a chemically synthesized peptide chain of 47 amino acids. The mechanism of action lies in its ability to bind strongly to the NTCP receptor on the surface of a hepatocyte involved in HBV penetration into the cell.ACHIEVED RESULTS /A phase Ia clinical trial has demonstrated the drugs safety and good tolerability. Phase IbIIa clinical trials are underway for Myrcludex B.MARKET POTENTIAL /Annually, around 50 million new cases of infection are diagnosed and roughly 2 million people die worldwide from liver infections: cirrhosis of the liver and liver cell carcinoma, as well as acute fulminant hepatitis.THE TEAM /OKSANA MARKOVA,CEO;PAVEL BOGOMOLOV,PhD in Medicine, Medical Consultant;ALEXANDER ALEXANDROV,Development Advisor.PROJECT PARTNERS:Biotech company MYR, GmbH (Germany).DEVELOPMENT AND COMMERCIALIZATIONOF A DRUG FOR TREATING CHRONICHEPATITIS B AND CHRONIC VIRALHEPATITIS DHEPATERA LLCCONTACTS /MoscowOksanaMarkova+7 (495) 411 69 92hepatera@gmail.comul. BolshayaYakimanka, 1www.hepatera.ru 44. 45ANTI-VIRAL DRUGS, VACCINES AND DIAGNOSTICSCOMPETITIVE ADVANTAGES /The new drug has a novel mechanism of action, which opens up the important market sector of antiretroviral therapy. It has significantly greater efficacy than competing developments. In addition, the target matrix protein p17 of the human immunodeficiency virus (HIV) is one of the most conservative in the HIV genome, which should reduce the risk of drug resistance.MAIN POINTS OF INNOVATION /Small molecules designed using computer modeling inhibit the activity of HIV matrix protein p17 and suppress virus replication in the cell. The new drugs have fundamentally novel mechanisms of action.ACHIEVED RESULTS /Preclinical studies have begun. HIV matrix protein p17 inhibitors have high activity and low toxicity. Patent applications have been submitted in Russia, Germany, USA, and Japan; 7 articles have been published in foreign scientific journals.MARKET POTENTIAL /The fight against HIV is one of the top priorities of modern healthcare. The global sales market for antiretrovirals is more than 20 billion dollars; 35% of these sales are in Russia.THE TEAM /PETER FEDICHEV,CEO, CSO, head of R&D;MAXIM KHOLIN,Deputy of CEO;ALEXANDER KADUSHKIN,Head of chemistry department, medical chemistry;TIMOFEY PYRKOV,Chief research worker, head of drug development, including pre-clinical and clinical trials;Evgeny Getmantsev,Head of development and usage of IT in drug research and analysis of experimental data.HIV MATRIX PROTEIN MA/P17INHIBITORS FOR TREATING HIV/AIDSQUANTUM PHARMACEUTICALS LLCCONTACTS /MoscowMaxim Kholin+7 (499) 156 15 61+7 (499) 150 83 32maxim.kholin@q-pharm.comwww.q-pharm.com 45. 46 46. 47DEVELOPMENT OF A NEWGENERATION OF ANTIFUNGALCOMPOUNDS USING IN SILICOAND IN VITRO SCREENINGCOMPETITIVE ADVANTAGES /The new effective drug is the subject of interest of all the players, as it allows getting a significant share of the market in monetary terms due to the exclusive rights for its production.MAIN POINTS OF INNOVATION /Construction of new synthetic CYP51 inhibitors.ACHIEVED RESULTS /The analysis of chemical space is carried out. Selection of compounds that bind to target proteins of pathogens and do not interact with the xenobiotic metabolism system of the human body.MARKET POTENTIAL /Antifungal agents belong to the group with a high steady demand. The average yield from their sale is about 50-55%. The specific share of the total world market in USA is 35%, in Europe - 25%, in Japan -30%.THE TEAM /ALEXEY KLYUCHENOVICH,CEO;DMITRY MUKHA,Deputy CEO;ALEXEY YANTSEVICH,Head of the Operations in the Field of AnalyticalMethods and Chemical Synthesis;ANDREY GILEP,Head of Operations in the Field of Molecular Cloning;SERGEY USANOV,Project Coordinator.CONTACTS /MoscowAlexeyKlyuchenovichinfo@target-medicals.com; dmitry.mukha@iboch.bas-net.by127051, Russia, Moscow,Maliy Sukharevsky per., 9,build. 1, of. 36www.target-medicals.comTARGET MEDICALS LTD.MOLECULAR MODELING TOOLS, MOLECULAR INTERACTIONMODELS AND TOOLS 47. 48COMPETITIVE ADVANTAGES /The new drug can solve key problems in treating Parkinsons Disease: it increases the efficacy and safety of palliative treatment, slows disease progression, and eliminates non-motor symptoms.MAIN POINTS OF INNOVATION /The drug has an innovative mechanism of anti-Parkinsons action; it has advantages over known classes of anti-Parkinsons drugs and is potentially competitive on the global market.ACHIEVED RESULTS /Dozens of biologically active compounds have been synthesized and studied. These compounds have been compared for efficacy of anti-Parkinsons activity and safety of use. Safety and efficacy indices have been studied.MARKET POTENTIAL /For the Russian market, where imported anti-Parkinsons drugs dominate (over 85%), this is the first original drug in the segment that can replace imports.THE TEAM /VENIAMIN KHAZANOV,Doctor of Medicine, Professor, Project Manager;NARIMAN SALAKHUTDINOV,Doctor of Chemistry;NATALYA BELSKAYA,Doctor of Medicine, Deputy CEO.INNOVATIVE DRUG FORTREATING PARKINSONS DISEASERIONIS LLCCONTACTS /TomskVeniaminKhazanovantiparkinson@mail.ruRussia,Tomsk Oblast,Tomsk, ul. Elizarovykh,D. 79/4Normal brainBrain withParkinsons DiseaseNEUROLOGICAL DRUGS & DIAGNOSTICS 48. 49COMPETITIVE ADVANTAGES /Odelepran may have a more favorable efficacy-to-safety ratio compared to naltrexone.MAIN POINTS OF INNOVATION /Odelepran is a new opioid receptor antagonist that demonstrates high in vitroaffinity and antagonism toward all 3 types of human opioid receptors.ACHIEVED RESULTS /A series of preclinical studies have been completed, as well as phase I and II clinical trials of the tablet dosage form of Odelepran in patients with alcohol dependence.MARKET POTENTIAL /The market will grow as new drugs with proven efficacy appear. Naltrexone is the only effective drug for treating narcotic dependence available in Russia.ODELEPRAN: NEW OPIOIDRECEPTOR ANTAGONISTR-OPRA LLCCONTACTS /MoscowSergey Grishin+7 (963) 683 05 71sa.grishin@rpharm.ruul. Berzarina, 19,korp. 1NEUROLOGICAL DRUGS & DIAGNOSTICS 49. 50COMPETITIVE ADVANTAGES /Applying of a new type of fluorescent biocompatible markers on the basis of nanodiamond and nanographite. The expected parameters will drastically exceed those of domestic and foreign competitors.MAIN POINTS OF INNOVATION /An alternative approach to the development of luminescent nanodiamonds to be applied as biomarkers is based on chemical sedimentation of diamond from the gaseous phase (CVD method).ACHIEVED RESULTS /The work is carried out at the RAS Institute of General Physics laboratories, where experimantal plants for CVD diamond growth have been developed.MARKET POTENTIAL /The global biomarker market will grow from USD 5 bln (2009) to USD 20 bln (2014), oncobiomarkers from USD 4.1 bln (2009) to USD 9.5 bln (2014). The applications in cardio and central nervous system treatment in 2007 totaled 23% of the biomarker market.THE TEAM /IGOR VLASOV,RusNano scientific expert, CEO;VIKTOR RALCHENKO,PhD in Physics and Mathematics, CSO;VIKTOR LOSHCHENOV,Doctor of Physics and Mathematics, scientific expert;VITALY KONOV,Doctor of Physics and Mathematics, Prof., RAS corresponding member, scientific expert;TATIANA EGOROVA,investment analyst at NC TECHNOSPARK,development manager.BIOMEDICAL MARKERS ON THE BASISOF HIGH-STABLE LUMINESCENTCARBON NANOMATERIALSADAMARK LLCCONTACTS /TroitskIgor Vlasov+7 (916) 601 87 36mp@ttorr.ru1 Sirenevy bulvar,142190 Troitsk,Moscow region,RussiaTRANSLATIONAL (PERSONALISED) MEDICINE BIOMARKERS 50. 51PETAR: A NEW METHOD FOR PERSONALIZED TREATMENT OF CANCERAND AUTOIMMUNE DISEASESCOMPETITIVE ADVANTAGES /A personalized method of treating tumors and autoimmune diseases can reduce costs for purchasing expensive drugs for patients who do not respond to the standard treatment.MAIN POINTS OF INNOVATION /Determination of an individual set of targets for treatment based on a patients biological tissues; creation of patient- specific protein molecules based on the selected targets; administration of individualized medicine to the patient.ACHIEVED RESULTS /Sets (cassettes) of therapeutic antibodies are developed against individual tumor antigens, as well as cassettes of immunotoxins for destroying pathological B cells in autoimmune diseases.MARKET POTENTIAL /Individual targeted drugs based on immunotoxins against specific B cell clones, which develop autoantibodies against neuroantigens, as well as antibodies against cancer antigens for treating multiple sclerosis and several forms of cancer.CONTACTS /MoscowAlexanderGabibovivolodin74@mail.ruul. Miklukho-Maklaya,16/10, korp. 12PERSONALIZED TECHNOLOGIES DEVELOPMENTCENTER LLC (PETAR CENTER LLC)TRANSLATIONAL (PERSONALISED) MEDICINE, BIOMARKERSLevel of Healthvalidation of treatment methodtreatmentCost of treatmentBlockbuster treatmentPeTAR 51. CANCER DRUGS & DIAGNOSTICS53INNOVATIVE BIFUNCTIONALTARGET-SPECIFIC SMALL MOLECULEANTI-CANCER DRUGSCOMPETITIVE ADVANTAGES /Selectivity, wide spectrum of effects, high efficacy due to bifunctional action, reduced risk of drug resistance.MAIN POINTS OF INNOVATION /The new drugs cause programmed cell death of cancer cells by simultaneously inhibiting functionally distinct factors that regulate the growth and death of cancer cells.ACHIEVED RESULTS /A candidate drug has been selected.MARKET POTENTIAL /The global sales volume of anti-cancer drugs will reach 72 billion dollars in 2016.THE TEAM /VLADIMIR KUCHEROV,Director;GALINA SELIVANOVA;VLADIMIR POROYKOV;ALEXANDER KEL.CONTACTS /MoscowVladimir Kucherovcontact@a-lab.com.ruA-LABORATORY LLC 52. 54COMPETITIVE ADVANTAGES /Usage of Medicinal Nanoengineering platform. High efficacy of medicines in combination with reduced side effects and toxicity.MAIN POINTS OF INNOVATION /Accurins is accumulated in the target tissue and locally releases the active substance there. The result is the maximum therapeutic efficacy of the drug against the reduced toxicity related to its systemic administration.ACHIEVED RESULTS /The flagship product of Accurins class Bind-014 is currently under development in early Phase II clinical trials in patients with cancer in the United States and Russia.MARKET POTENTIAL /Accurins technology can be used both for existing drugs, and for compounds that are under development, which allows producing the best-in-class drugs.THE TEAM /ELMIRA SAFAROVA,PhD., CEO;JEFF HRKACH,PhD., Scientific Consultant;STEPHEN ZALE,PhD., Scientific Consultant;NATALIA SAMSONENKO,MBA, Financial Director;ARKADY ZINCHENKO,PhD., Head of the Preparation of Dosage Forms Department;DMITRY ANDREEV,PhD., Head of Analytic Department.DEVELOPMENT OF MEDICINES BASED ON THE TARGETED POLYMERICNANOPARTICLESBIND (RUS) LLCCONTACTS /MoscowElmira SafarovaElmiraSafarova@bindtherapeutics.com117246, Russia, Moscow, Nauchnyiproezd, 20, bldg. 2 www. bindtherapeutics.comCANCER DRUGS & DIAGNOSTICS 53. 55CANCER DRUGS & DIAGNOSTICSCOMPETITIVE ADVANTAGES /Versatility of action, low toxicity, high specificity. Inhibition of telomerase:- Reduces the potential of malignant cells division;- Destroys the primary tumor and metastases;- Decreases the ability of the primary tumors to metastasize.MAIN POINTS OF INNOVATION /The drug developed under the project shall have substantially lower toxicity (analogues of this class of compounds, according to published data, do not have high toxicity) and greater selectivity for tumor cells.ACHIEVED RESULTS /Testing of compounds panel (search for more active compounds with improved physico-chemical properties). Conducting in vivo studies - evidence of the antitumor activity of compounds affecting the assembly of the enzyme.MARKET POTENTIAL /The world market of anticancer drugs is USD 80 billion. The developed drugs will have a significantly lower cost compared to the analogues with the effect not inferior to them.THE TEAM /MARIA ZVEREVA,Project Manager;ALEXANDER MAZHUGA,CEO;ALEXANDER KABANOV,Scientific Consultant;OLGA DONTSOVA,Scientific Consultant.SYNTHESIS AND PRE-CLINICAL TRIALSOF A NEW TYPE OF ANTICANCER DRUGS, TELOMERASE INHIBITORSONCOBIOTECH LLCCONTACTS /MoscowAlexander Mazhugamaguga@mail.ru119311, Moscow,pr-t Vernadskogo, 15, apt. 316 54. CANCER DRUGS & DIAGNOSTICS56DEVELOPMENT AND COMMERCIALIZATION OF VACCINES BASED ON NANOPARTICLESCOMPETITIVE ADVANTAGES /Synthetic vaccines have:- Higher efficacy- Enhanced safety profile through targeted delivery- Short production cycle due to the synthetic components- A lower cost of manufacturing process.MAIN POINTS OF INNOVATION /Synthetic vaccines produced by Selecta based on tSVP nanoparticles are designed to meet the most current knowledge about immune system acting to produce an optimal immune response.ACHIEVED RESULTS /1. The experimental results have confirmed the concept of vaccine acting against cancer.2. Phase I clinical trials of anti-nicotine vaccine has been completed.MARKET POTENTIAL /1. The market of immuno-oncology drugs will reach USD 1.5 billion by 20182. The market of agents for smoking cessation aid will reach USD 4.5 billion by 2018THE TEAM /WERNER CAUTREELS,CEO;DMITRY OVCHINNIKOV,Deputy CEO;NATALIA BASTRIKOVA,Director of Corporate Development and Clinical Research.CONTACTS /MoscowNatalia Bastrikovanbastrikova@selectarus.com141400, Russia, MoscowRegion, Khimki,ul. Rabochaya, 2 a, build 1www.selectabio.comSELECTA (RUS) LLC 55. 57CANCER DRUGS & DIAGNOSTICSCOMPETITIVE ADVANTAGES /A unique mechanism of TAV08 action on the key stages of pathogenesis by restoring the balance of different types of cells, but not by eliminating the consequences of autoimmune disease pathogenesis.MAIN POINTS OF INNOVATION /An unique Russian drug for a treatment of B-cell chronic lymphocytic leukemia and autoimmune diseases.ACHIEVED RESULTS /The first phase of clinical trials for TAB08 has been completed.Since the launch of the project, 10 international patents (PCT, US), including the developed in-vitrotechnology resTore, have been received.All intellectual property is owned by TheraMAB LLC.MARKET POTENTIAL /Involving an additional round of funding will allow completing Phase 3 clinical trials for TAV08 in the Russian Federation or other countries and launch TAV08 in the market.At the moment, there is an evidence of a powerful therapeutic potential of TAV08.THE TEAM /DMITRY TYRSIN,PhD University of Wrzburg, CEO.ALEXEY MATSKEVICH,PhD in Biological Sciences, Research Director.YURI FEDOTOV,Pre-clinical and Clinical Research Director.MIKHAIL PANTELEEV,PhD in Biological Sciences, Head of ScienceDepartment.DANIIL NEMENOV, Clinical Research Manager.MEDICINE FOR A TREATMENTOF AUTOIMMUNE DISEASES AND CHRONIC LYMPHOCYTIC LEUKEMIA HAVINGA POWERFUL THERAPEUTIC POTENTIALTHERAMABCONTACTS /MoscowDmitry Tyrsin+7 (495) 974-74-01tyrsin@bioprocess.ruwww.theramab.ru 56. CANCER DRUGS & DIAGNOSTICS58COMPETITIVE ADVANTAGES /The developed diagnostic system will allow:- Excluding the costs for the therapy known to be ineffective,- Avoiding selection of drugs by trial and error method,- Increasing effectiveness of oncology patients treatment.MAIN POINTS OF INNOVATION /System diagnostics and personalized selection of the optimal cancer treatment will allow to detect numerous defects in a tumor, and at the same time to analyze them using proprietary technology in the automatic mode.ACHIEVED RESULTS /Diagnostic panel and analytical software have been designed, tested and optimized for inclusion into the Silver, Gold and Platinum versions. In collaboration with N. N. Blokhin Russian Cancer Research Center, a range of evidences of the system effectiveness has been obtained.MARKET POTENTIAL /The diagnostic system will be available in three versions that will differ in cost and type of diagnostics, a doctor and a patient will be able to choose the most appropriate one.THE TEAM /TATIANA NIKOLSKAYA,CEO;SERGEY TYULYANDIN,Head of the Clinical Part of the Project;ALEXANDER KHVAT,Head of Medical and Chemical Part of the Project;MIKHAIL FEDYANIN,Associate Contractor in the Clinical Part of the Project.PROJECT PARTNERS:N. N. Blokhin Russian Cancer Research Center.IMPLEMENTATION OF TECHNOLOGYFOR EARLY DIAGNOSIS, SELECTIONOF INDIVIDUAL DRUG COMBINATIONSAND PERSONALIZED MEDICINEIN ONCOLOGY IN RUSSIARUSGENDIAGNOSTICS LLCCONTACTS /KhimkiTatiana Nikolskayatnikolsk@gmail.com 141400, Russia,Moscow Region, Khimki,ul. Rabochaya, 2a,bldg. 1 57. 59CANCER DRUGS & DIAGNOSTICSSTUDY OF RPT835: A SMALL MOLECULEINHIBITOR OF FIBROBLAST GROWTHFACTOR RECEPTOR 2 IN THE TREATMENT OF MALIGNANT TUMORSCOMPETITIVE ADVANTAGES /The new drug blocks both hot spots (pharmacophore centers) and atypical bonds for blocking inside the receptor (know-how). The chemical structure is unique. It interacts specifically with one receptor and is classified as a targeted drug. It is less toxic; dose escalation may not be required due to selective action solely on a section of the FGFR2.MAIN POINTS OF INNOVATION /In contrast with other targeted drugs on the market or in development, RPT835 selectively blocks specific sections of fibroblast growth factor receptor 2 (FGFR2) without affecting other receptors, which significantly suppresses the growth of refractory malignant tumors while simultaneously reducing side effects. Cutting-edge biochemical technology is used to produce the drug.ACHIEVED RESULTS /- the molecule and modifications have been developed;- de novo studies have confirmed the molecules action on receptor active centers;- by October 2012, the amount of RPT835 needed for the first phase of preclinical efficacy studies (in vitro studies) had been chemically synthesized, and the physical and chemical properties of the active ingredient had been described;- in October 2012, in vitro studies demonstrated the drugs effect on phosphorylation of fibroblast growth factor receptor 2, i.e., the main mechanism that activates the receptor;- in March 2013, in vivo studies were completed on RPT835s effect on angiogenesis in mice;- the drug is currently in the preclinical study stage.THE TEAM /TAMARA TIMOFEEVA,CEO;SERGEY TULYANDIN,Chief scientific officer;ILYA TIMOFEEV,Scientific consultant;MIKHAIL BIAKHOV,Project coordinator;CONTACTS /St. PetersburgIlya Timofeevoffice@ruspharm.com190103, St. Petersburg, ul.11-ya Krasnoarmeyskaya, dom 16, liter A,pomeshchenie 5-N+7 (812) 937 29 65www.ruspharm.comRUSSIAN PHARMACEUTICAL TECHNOLOGIES LLC 58. CANCER DRUGS & DIAGNOSTICS60COMPETITIVE ADVANTAGES /High bioavailability of DIM provides effective concentrations of the active substance in the lesions. High selectivity of the active substance relative to the transformed cells. No severe toxicity and side effects.MAIN POINTS OF INNOVATION /The first low-toxic anticancer drug with selective inhibitory activity against tumor stem cells, which are the source of tumor recurrence and metastasis.ACHIEVED RESULTS /Preclinical studies have been completed, pharmacokinetics and pharmacodynamics of the drug have been studied. Preclinical studies of specific pharmacological activity in vitro have been completed as well as the effectiveness of the drug in vivo.MARKET POTENTIAL /The market volume of drugs used in Russian Federation for the treatment of oncology diseases of reproductive system is USD 200 million Forecast of the sector development up to 2015 is minimum USD 1 billion.THE TEAM /VSEVOLOD KISELEV,Research Manager;KUSHLINSKY NIKOLAY,FAZLUL H. SARKAR,International Consultants;DMITRY SIDORIN,Engineer, Production of Drugs Consultant; GEORGIY FRANK,Study Doctor in Clinical Trials;RUSTEM KHASANOV,Study Doctor.DEVELOPMENT OF A NEW DRUGFOR TREATMENT OF THE HUMANREPRODUCTIVE SYSTEM CANCERSANO NATIONAL INSTITUTE OF INNOVATIONCONTACTS /MoscowVsevolod Kiselev+7 (495) 989 45 93info@anonii.ru123100, Russia,Moscow,Presnenskaya nab., 12www.anonii.ru 59. 61CANCER DRUGS & DIAGNOSTICSCOMPETITIVE ADVANTAGES /The key differences of the product from existing solutions and new products:- The possibility of mass production;- High efficiency for many types of solid malignant tumors;- The possibility of tumor development prevention.MAIN POINTS OF INNOVATION /The proposed product is developed as a non-individualized vaccine that is suitable for treatment of various forms of solid tumors.ACHIEVED RESULTS /Technical specifications of the product, achieved at this stage: the efficacy on animal models is more than 60%.Completion of PRAV vaccine prototype is planned to achieve the treatment rates efficacy in humans of up to 70%.MARKET POTENTIAL /Mass production of PRAV vaccine will lead to treatment accessibility for many types of solid tumors. PRAV vaccine which is under development will have global competitiveness.THE TEAM /OLEG KRYLOV,CEO;RUSTEM AMIROV,Deputy CEO;ALEXANDER POLETAEV,Research Project Manager;SHAMIL GANTZ,Chief Consultant in Oncology;ANDRES BREDBERG,Consultant in Molecular Studies.PROJECT PARTNERS:CJSC Managing Company Savings and Investments.DEVELOPMENT OF A NON-INDIVIDUALIZED METHOD OF SPECIFIC IMMUNOTHERAPYOF MALIGNANT SOLID TUMORSA-VAK LLCCONTACTS /MoscowOleg Krylovkrylov@immunculus.ru127254, Russia, Moscow,ul. Rustaveli, 3,block 7, apt. 9 60. CANCER DRUGS & DIAGNOSTICS62INNOVATIVE LUMINESCENTNANOMATERIALS AND TECHNOLOGIESFOR THEIR APPLICATION IN BIOMEDICINECOMPETITIVE ADVANTAGES /Luminescent nanocrystals with unique ability to convert the driving infrared radiation into luminescence in the visible and infrared ranges: solution of the tissue autofluorescence problem, clear visualization of the labeled lesions boundaries.MAIN POINTS OF INNOVATION /Pathological tissues are labeled with the targeted fluorescent molecular probes.ACHIEVED RESULTS /Technical risks of the project can be deemed minimal. The synthesis of anti- Stokes nanophosphors, solegated by erbium and thulium ions, was developed. The stability of surface-modified NAPhs has been confirmed.MARKET POTENTIAL /The proposed technology is competitive on the domestic and global markets and can have a positive impact on import substitution.THE TEAM /VLADIMIR SOKOVIKOV,CEO;ANDREY ZVYAGIN,Research Manager;ANDREY NECHAEV,Expert in Chemical Synthesis;ANNA GULLER,Expert in Biomedical Research;PROJECT PARTNERS:STC Amplitude LLC.CONTACTS /MoscowAndreyZvyaginmithrelfluoro@gmail.comRussia, Moscow,ul. Lyapidevskogo 10,apt. 41MITHREL-LUMITEC LLC 61. 63CANCER DRUGS & DIAGNOSTICSCOMPETITIVE ADVANTAGES /Previously, this molecule has never been used as a target in the treatment of renal cell carcinoma. New drug is capable of inhibiting tumor growth by more than 90%, has low immunogenicity and toxicity due to the high levels of human protein (93%).MAIN POINTS OF INNOVATION /OM-RCA-01 is an antiangiogenic drug on the basis of monoclonal antibodies to the fibroblast growth factor receptor for cancer treatment.ACHIEVED RESULTS /Antibody humanization has been performed;producer has been developed.Efficacy in vitro and in vivo has been confirmed.Preclinical safety studies were initiated.Patents have been received in the Russian Federation and USA.6 scientific articles, including articles in the International Journal of Cancer, have been published.MARKET POTENTIAL /Drugs based on monoclonal antibodies to fibroblast growth factor receptor are practically unavailable on the market.The market of drugs for the treatment of renal cell carcinoma (United States, Japan and the EU) is about $ 950 million. Russian market capacity is about 5 billion rubles.THE TEAM /ELINA ZAVELEVA,PhD (Biology), CEO.ILYA TIMOFEEV,Scientific Consultant, author of development.ANTON TIKHONOV,Project ManagerCOMPANY PARTNERS:Research and Development PXTherapeutics,Goodwin Biotechnology, Genetika, EUGENEXBiotechnologies, Charles River.Companymanagement Maxwell Biotech Group.NEW LOW-TOXICITY DRUG FOR KIDNEY CANCER TREATMENTONCOMAXCONTACTS /MoscowElina Zaveleva+7 (495) 411-69-92/93info@oncomax.ruwww.oncomax.ru 62. CANCER DRUGS & DIAGNOSTICS64THE PORTFOLIO OF ANTICANCER DRUGSUNDER DEVELOPMENT BASED ON NOVEL SCIENTIFIC CONCEPTOF ANTI-TISSUE CHEMICAL SURGERYCOMPETITIVE ADVANTAGES /The new drug may solve the problem of insufficient selectivity of the existing anticancer drugs and prevent development of drug-resistant and metastatic tumor types, reduce the severity of chemotherapy side effects.MAIN POINTS OF INNOVATION /The new approach based on the principle of specificity to the body tissues, a kind of pharmacological surgery, opens the opportunities of creating a principally novel class of anti-tumor agents.ACHIEVED RESULTS /Perspective hit compounds have been obtained; they are currently being characterized and optimized, most likely modes of action and efficacy in animal models are being investigated.MARKET POTENTIAL /The cancer types, which the project aims to, make up above 40% of all registered oncology diseases. The global market of anticancer drugs is currently approximating USD 100 bln.THE TEAM /ANDREY GUDKOV,Doctor of Biology, Prof., scientific initiator of theproject;OLGA CHERNOVA,PhD in Biology, head of R&D;ALEXANDER POLINSKY,PhD in Chemistry, president of the company;ANDREY LEONOV,PhD in Chemistry, CEO, OncoTartis LLCPROJECT PARTNERS:Roswell Park Cancer Institute (RPCI) (Buffalo, NewYork, USA).ONCOTARTIS LLCCONTACTS /MoscowAndrey Leonov+7 (495) 974 74 01(ext. 245)leonov@bioprocess. ru Bldg. 2, 6 Stolovypereulok,121069 Moscow,Russia 63. 65CANCER DRUGS & DIAGNOSTICSCOMPETITIVE ADVANTAGES /The efficacy and safety of anticancer drugs with a new mechanism of action has been proved by direct measurements of the enzyme.MAIN POINTS OF INNOVATION /All drugs developed in the framework of the project act against the same targeted molecule, glycolytic enzyme of 6-phosphofructo-2-kinase/fructose-2,6 biophosphatase-3 (PFKFB3). Current enzyme is overexpressed in the different types of tumor lines, thus, it provides broad spectrum of drugs action.ACHIEVED RESULTS /Several classes of compounds with anticancer activity confirmed in-vitro and in-vivo were obtained. The developed analogues show the activity and the therapeutic window on the same level or better than the molecules developed by competitors.MARKET POTENTIAL /Development of an effective and safe anticancer drug with the new mechanism of action. The colon and pancreatic cancer morbidity is growing, therefore, providing high market potential for the drug under development.THE TEAM /PETR FEDICHEV,CEO;TATIANA ZHIDKOVA,Research Assistant;TIMOFEY PYRKOV,Research Assistant.DEVELOPMENT OF GLYCOLYSISREGULATORS AS A NEW CLASSOF MEDICINESQUANTUM AGE LLCCONTACTS /MoscowPetr Fedichevglikoliz3@gmail.comRussia, Moscow,ul. Profsouznaya, 26/44,of. II, r. 1 64. CANCER DRUGS & DIAGNOSTICS66DRUGS FOR TREATING ONCOLOGICAL AND NEUROLOGICAL DISEASES BASEDON NANOSCALE DELIVERY SYSTEMTECHNOLOGIES (NANOMEDICINE)COMPETITIVE ADVANTAGES /The proposed delivery systems allow drugs to efficiently penetrate into the nidus via directed transport. Delivery systems provide a 1.53-fold increasein drug bioavailability, efficacy, and safety.MAIN POINTS OF INNOVATION /The key element is a drug delivery system using lactic and glycolic acid copolymers (50350 nm nanoparticles) and a medicine delivery system using albumin particles (100350 nm nanoparticles).ACHIEVED RESULTS /The developed drugs are in the early and late stages of preclinical studies.MARKET POTENTIAL /In 2009 the global market of drug delivery systems was worth over 100 billion dollars, and it is forecasted to grow to 200 to 700 billion dollars by 2015.The market for neurological, oncological, and genetic drugs comprises over 55% of the entire pharmaceutical market.THE TEAM /YASIR HAMDY,CEO.PROJECT PARTNERS:Frankfurt University;Kings College London;Geneva Foundation for Medical Education and Research,WHO Collaborating Centre;CNRS Research Institute of Biotechnology, France;I.M. Sechenov First Moscow State Medical University of the Russian Federation Ministry ofHealth and Social Development.LEKSYSTEMS LLCCONTACTS /MoscowYasirHamdyy_hamdy@mail.ru,denistom@mail.ru;ul. Skakovaya, 32, build. 2 65. 67CANCER DRUGS & DIAGNOSTICSTECHNOLOGY FOR PREDICTINGRECURRENCES AND CHEMOTHERAPYSENSITIVITY IN PATIENTS WITH BREASTCANCER BASED ON GENE EXPRESSION ANALYSISCOMPETITIVE ADVANTAGES /A unique gene pattern in a panel and a unique algorithm to calculate recurrence risk, accessible to consumers in Russia, relatively low cost. There are no Russian analogs.MAIN POINTS OF INNOVATION /The new technology creates a system to determine the gene expression profile for malignant tumors to identify groups of patients with stage IIIa breast cancer with high and low risk of distant metastasis.ACHIEVEDRESULTS /A bank has been created with 370 paraffin wax-embedded tissue samples. A method has been developed for obtaining results from the morphological description stage before results of gene expression are obtained.MARKET POTENTIAL /This innovation has the potential to achieve structural shifts in the industry or significant changes in technologies used and/or process costs.THE TEAM /VLADIMIR BOZHENKO,Doctor of Medicine, Professor, PhD in Biology, Project ResearchAdviser;OLEG BLIZNYUKOV,Doctor of Medicine, Pathomorphologist, Research Consultant;ELENA KUDINOVA,PhDin Medicine, Clinical Diagnosis Laboratory Doctor, Research Consultant; SERGEY KARBAINOV,Business Consultant.CONTACTS /MoscowVladimir Bozhenko+7 (495) 778 75 88bbii@mail.ru, polidar@ yahoo.comRussia, Moscow,ul. SalyamaAdilya, 9, off. 1, room 2GAMMA GLOBAL LLC 66. CANCER DRUGS & DIAGNOSTICS68COMPETITIVE ADVANTAGES /The products key distinction is the ability to simultaneously increase reliability and decrease the overall cost of analysis of oncomutations. The developers have obtained experimental proof of concept for a technology to detect one mutant DNA molecule in over 100,000 molecules without mutations.MAIN POINTS OF INNOVATION /The new approach combines specialized DNA sample preparation and a unique bioinformatics method for processing sequencing data, which eliminates internal technical error of the methods used.RESULTSACHIEVED /Test systems for high-precision analysis of oncomutations:2013: CancerSnap-7 test system prototype produced2014: CancerSnap-50 test system in developmentMARKETPOTENTIAL /The company plans to release the product to the clinical market in 2016.THE TEAM /ANDREY ZARETSKY,Test Systems Design and Validation Manager;DMITRY SHAGIN,Research and Development Manager;IVAN VOLCHENKOV,Bioinformatician/Programmer;TIMOFEY PANFILOV,CEO.MENTORS /SERGEY ANATOLYEVICH LUKYANOV, Russian Academy of Sciences Academician;NIKOLAY VLADIMIROVICH ZHUKOV, Clinical Oncology Director at the Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev.THE TECHNOLOGY OF DIFFERENTIALANALYSIS OF ONCOMUTATIONS IN COMPLEX DNA SAMPLES (DAOCS) FOR EARLYNONINVASIVE GENETIC TESTINGFOR CANCERNOVEL MOLECULAR TECHNOLOGIES LLC (NOMOTECH)CONTACTS /MoscowTimofey Panfilov117997, Russia, Moscow,ul. Miklukho-Maklaya,d. 16/10, korp. 15+7 (495) 988 40 83www.nomotech.rudaoss@nomotech.ru 67. 69CANCER DRUGS & DIAGNOSTICSCOMPETITIVE ADVANTAGES /The drug acts directly on several targets in the tumor cell, reducing its ability to produce drug resistance and increasing the efficiency of tumor growth suppression. Due to the lack of genotoxicity, safe long-term use is possible.MAIN POINTS OF INNOVATION /A new class of drugs (first-in-class), fundamentally different from the existing drugs developed by other international companies by the mechanism of action and efficacy. Curaxins do not cause DNA damage, as opposed to conventional chemotherapeutic agents.ACHIEVED RESULTS /- CBL0102Phase I clinical trials (RF) have been completed. PhaseI/II clinical trials in combination with erlotinib (USA) were launched.- CBL0137Equator of Phase I clinical trials (RF).Start of Phase I clinical trials (USA).Date of drug release is 2016 in theRussian Federation, 2018 in the USA.Worldwide patents are owned by Incuron LLC.10 invention patents, 26 international applications that during 2013-2014 will become national patents covering the worlds pharmaceutical market.MARKET POTENTIAL /Oncological diseases hold the leading positions in the structure of morbidity and mortality. Segment of targeted anticancer drugs is 65-70% of the total market.THE TEAM /ANDREY LEONOV,PhD in Chemical Sciences,CEO.ROMAN IVANOV,PhD in Chemical Sciences.RAMIZ SALIMOV,Doctor of Biological Sciences.POLINA SHPIGOTSKAYA,PhD in MedicalScience.ANDREY GUDKOV,Doctor of Biological Sciences,Roswell Park Cancer Institute.ANDREYPURMAL,PhD in Chemical Sciences,Cleveland Biolabs.NOVEL CANCER DRUG THATDOES NOT CAUSE NORMAL DNA DAMAGEINCURONCONTACTS /MoscowAndrey Leonov+7 (495) 974-74-01info@incuron.ruwww.incuron.ruwww.incuron.com 68. CANCER DRUGS & DIAGNOSTICS70DEVELOPMENT OF A DEVICE FORHIGH-VALUE INSTANT DIAGNOSIS OFPROSTATE CANCER BASED ON THE ANALYSIS OF PROSTATIC SECRETIONS AND EJACULATECOMPETITIVE ADVANTAGES /The developed product will be in demand on the market at the time of commercialization due to the considerably higher sensitivity and lower price. There are no Russian and foreign analogues of this test.MAIN POINTS OF INNOVATION /The levels of certain biomarkers of non-protein origin are measured in the prostatic secretions and/or ejaculate. The sample is evaluated using colorimetric, enzymatic and electrochemical methods.ACHIEVED RESULTS /An application is filed for obtaining an international patent for the product. Development and creation of a portable diagnostic device. Clinical trials of a portable diagnostic device.MARKET POTENTIAL /The developed test can replace the PSA test and drive the latter out of the market of prostate cancer diagnostics both in Russia and abroad.THE TEAM /MAXIM ROSSMANN,PhD, Project Director;DMITRY SOLOVYOV,PhD in Chem. Sc., Research Project ManagerIRINA SOLMATOVA-SOLOVYEVA,CEO;PAVEL SHASHKOV,PhD in Phys-Math. Sc., Commercial Director;ISTVAN BOROS,PhD, Intellectual Property Development;SERGEY USOV,Business Consultant.CONTACTS /St. PetersburgIrinaSolmatova-Solovyeva+7 (812) 635 75 44office@camonx.comRussia, 191014, St.Petersburg,ul. Vosstania 30/7, build.A, of. 11-www.camonx.comONCOMETRIX LLC 69. 71CANCER DRUGS & DIAGNOSTICSIMMUNOTHERAPY OF B CELLMALIGNANT DISEASESCOMPETITIVE ADVANTAGES /Generiums bispecific molecule demonstrates higher killing of malignant cells and improved drug tolerability properties.MAIN POINTS OF INNOVATION /The molecule recognizes a B cell marker that is found in a wide range of hematologic malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and various types of non-Hodgkin lymphomas.ACHIEVED RESULTS /The project will involve creating a bispecific antibody (BsAB) aimed at engaging cytotoxic effector cells of the human immune system against lymphoma B cells.MARKET POTENTIAL /In comparison with other BsAB designs, Generiums bispecific molecule demonstrates higher killing of malignant cells and improved drug tolerability properties.THE TEAM /SERGEY RUCHKO,CEO;DANIIL TALYANSKY,Chief Business Officer;ANDREY PETROV,Chief Science Officer;MAXIM LYKOV,COO;IGOR GOVOROV,CTO.CONTACTS /MoscowDaniil Talyansky+7 (495) 989 46 75tds@ibcgenerium.ruul. Testovskaya, 10GENERIUM INTERNATIONALBIOTECHNOLOGY CENTER LLC 70. CANCER DRUGS & DIAGNOSTICS72COMPETITIVE ADVANTAGES /1. sensitivity and specificity of 9598% (better than any other cancer diagnosis methods)2. detects all types of cancer3. effective even at early stages of disease4. requires only 0.2 ml of blood plasma (no biopsy needed)5. quick (24 hours), inexpensive (cost price approximately $250)MAIN POINTS OF INNOVATION /The test is based on analyzing methylation of free circulating DNA. A unique DNA amplification method allows for analysis of methylation of the entire genome using 0.2 ng of DNA. A method has been developed to select biomarkers for the entire genome, which achieves sensitivity and specificity of 9598%.ACHIEVED RESULTS /A DNA amplification technique has been developed, a platform has been created to search for biomarkers, and candidate biomarkers have been selected. Preliminary studies of M-TEST: 1 error in 33 samples, test duration 24 hours, test cost price approximately $250.MARKET POTENTIAL /M-TEST can be used for cancer screening (universal test for all types of cancer), for confirming diagnosis, and for monitoring treatment efficacy. The global market of innovative cancer diagnostics is estimated to be $2.5 billion, with CAGR of 45%.THE TEAM /ANATOLY MELNIKOV,Project Director. Over 10 years of research in the project subject matter, several patents, and dozens of publications.EGOR MELNIKOV,CEO.Founder of several successful startups.GEORGY NIKITIN,Commercial Director. Private equity fund investment department manager.VIKTOR LEVENSON,Scientific Consultant. Co-founder of USBiomarkers.DIAGNOSIS OF ONCOLOGICALDISEASES VIA ANALYSIS OF DNACIRCULATING IN BLOOD PLASMA (M-TEST)BIOMARKER-RU LLCCONTACTS /MoscowEgor Melnikov+7(495)502-2196me@l27.ru,biomarker.ru@gmail.comwww.bio-marker.ru,www..(under construction)M-TEST early in vitro cancer diagnosis 71. 73CANCER DRUGS & DIAGNOSTICSINNOVATIVE TEST SYSTEMS FORDIAGNOSING ONCOLOGICAL DISEASES BASED ON INDEPENDENTLY DEVELOPED AND PRODUCED ANTIBODIES AGAINSTNEW TUMOR MARKERSCOMPETITIVE ADVANTAGES /The new test systems will perform diagnosis using peripheral blood serum and will not require a biopsy, which will clearly improve the patients quality of life.MAIN POINTS OF INNOVATION /Development of novel monoclonal antibodies and innovative noninvasive tests that improve the diagnosis of several types of malignant tumors for which there are currently no simple diagnostic methods.ACHIEVED RESULTS /Increased expression of several new markers for gliomas and glioblastomas has been shown.MARKET POTENTIAL /The market of tests to determine tumor molecular markers was worth $150 billion in 2010. This segment is expected to grow to $300 billion by 2015.THE TEAM /ALEXEY GRACHEV,Doctor of Biology,CEO;YULIA KZHYSHKOVSKA,Doctor of Biology, Professor,Project Director;OLGA KOVALEVA,PhD in Biology;VASILY KHOMENKOV,PhD in Biology.CONTACTS /MoscowAlexey Grachev+7-(499)-645-50-45info@primebiomed.ruwww.primebiomed.ruPRIMEBIOMED LLC 72. 74CANCER DRUGS & DIAGNOSTICSNEW TYROSINE KINASE INHIBITORSAS POTENTIAL ANTI-CANCER DRUGSCOMPETITIVE ADVANTAGES /PF-114 is effective in treating all known mutational resistant forms of Ph+ leukemias and has a high selectivityof action.MAIN POINTS OF INNOVATION /PF-114 is a next-generation targeted inhibitor of Bcr/Abl for treating Ph+ leukemias.ACHIEVED RESULTS /The efficacy of PF-114 has been confirmed in in vitro and in vivo models of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemias, including the most resistant forms of the disease with the T315I mutation. The drugs good safety profile has been confirmed in in vivo toxicology experiments.MARKET POTENTIAL /The new drug has the potential to take up to a third of the global market for treating resistant forms of Ph+ leukemias.THE TEAM /GHERMES CHILOV,PhD in Chemistry, CEO.The team of developers includes specialists in medicinal chemistry, leukemia biology, and preclinical studies.FUSION PHARMA LLCCONTACTS /MoscowGhermesChilov+7 (499) 135 53 13ghermes@ruspharmtech.ruul. GeneralaDorokhova,18, build. 2 73. 75CANCER DRUGS & DIAGNOSTICSCOMPETITIVE ADVANTAGES /The screening system at the leading cancer treatment establishments of the country will enable to increase cancer detectability. More than 150 major medical institutions of the Russian Federation may be equipped in the initial phase.MAIN POINTS OF INNOVATION /The hardware and software complex being developed will become a centralized self- learning databank of known neoplasms with the feature of simultaneous connection of the required number of subscribers.ACHIEVED RESULTS /The project undergoes the phase of working design documentatio